Tag: ai-powered diagnostic radiogenomics devices market research

  • Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Size In 2026 And Beyond: Understanding Future Growth Potential

    Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Size In 2026 And Beyond: Understanding Future Growth Potential

    Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

    Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Forecast: What Value Will The Market Reach By 2030?

    The market for artificial intelligence (AI)-powered diagnostic radiogenomics devices has experienced swift expansion recently. This market is projected to expand from $0.62 billion in 2025 to $0.74 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 19.2%. Historically, this expansion has been driven by factors such as the increasing occurrence of chronic and complex illnesses, the greater uptake of sophisticated diagnostic imaging techniques, increased funding for precision medicine research, the broadening scope of genomic sequencing and molecular profiling applications, and the rising need for data-driven solutions in clinical decision-making.

    The market for artificial intelligence (AI)-powered diagnostic radiogenomics devices is anticipated to experience substantial expansion in the coming years. This market is projected to reach $1.5 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 19.5%. This growth during the forecast period can be attributed to several factors, including a heightened demand for AI-enabled personalized treatment planning, the increasing embrace of cloud-based radiogenomic data analytics platforms, the expanding integration of genomics into diagnostic imaging workflows, greater investment in precision diagnostics for oncology and neurology, and an elevated focus on early disease detection and predictive healthcare technologies. Key trends expected during this period involve the rising adoption of platforms that integrate multimodal imaging and genomics, a surging demand for customized and precise diagnostic solutions, the expanding application of predictive analytics for assessing disease prognosis and therapy response, the increasing deployment of automated tools for radiogenomic data interpretation, and an enhanced emphasis on real-time clinical decision support within diagnostic workflows.

    Get A Free Sample Report With In-Depth Market Insights:

    https://thebusinessresearchcompany.com/sample_request?id=96296890&type=smp&name=Artificial%20Intelligence%20%28AI%29-Powered%20Diagnostic%20Radiogenomics%20Devices%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

    Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Demand Drivers Opening New Revenue Streams

    The future expansion of the AI-powered diagnostic radiogenomics devices market is anticipated to be fueled by the growing embrace of precision medicine approaches. These approaches involve medical strategies customized for disease prevention, diagnosis, and treatment, considering unique individual genetic makeup, environmental factors, and lifestyle choices. The heightened adoption of precision medicine primarily stems from the greater incorporation of genomic data into clinical decision-making processes within advanced healthcare systems. AI-powered diagnostic radiogenomics devices facilitate this trend through their ability to merge medical imaging with genomic information, thereby allowing for precise disease profiling, prompt diagnosis, and tailored treatment strategies. A notable example is provided by a February 2024 report from the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, which indicated that personalized therapies constituted more than one-third of new drug approvals by the U. S. Food and Drug Administration for four consecutive years up to and including 2023. Consequently, the expanding embrace of precision medicine approaches is a primary catalyst for the growth of the AI-powered diagnostic radiogenomics devices market.

    Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Segment Trends And Revenue Contributors

    The artificial intelligence (ai)-powered diagnostic radiogenomics devices market covered in this report is segmented –

    1) By Component: Hardware, Software, Services

    2) By Imaging Modality: Magnetic Resonance Imaging, Computed Tomography, Positron Emission Tomography, Ultrasound, X-Ray Or Mammography, Multi-Modal Fusion

    3) By Application: Oncology, Neurology, Cardiology, Infectious Diseases

    4) By End User: Hospitals And Clinics, Diagnostic Imaging Centers, Academic And Research Institutes And Biobanks, Pharmaceutical And Biotechnology Companies And Contract Research Organizations, Government And Public Health Programs

    Subsegments:

    1) By Hardware: Imaging Sensors, Computational Processing Units, Data Storage Systems, Networking And Connectivity Modules, User Interface Devices

    2) By Software: Radiogenomic Analysis Software, Artificial Intelligence Diagnostic Algorithms, Image Processing And Enhancement Software, Data Visualization And Reporting Tools, Machine Learning Model Management Software

    3) By Services: Installation And Setup Services, Calibration And Maintenance Services, Training And Support Services, Data Management And Integration Services, Clinical Workflow Optimization Services

    Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Trends Powering Strategic Industry Growth

    Leading companies in the AI-powered diagnostic radiogenomics devices market are increasingly concentrating on technological advancements like imaging quality assessment tools to improve diagnostic accuracy and consistency. An imaging quality assessment tool is a software system that employs advanced algorithms to evaluate, standardize, and ensure the dependability of medical imaging data. For instance, in June 2025, Quibim, a Spain-based medical imaging technology company, launched AI-QUAL, a solution that applies artificial intelligence to automatically assess prostate magnetic resonance imaging quality, assign standardized scores, and detect artifacts that could compromise diagnostic outcomes. The tool streamlines radiology workflows and supports more reliable clinical decision-making by guaranteeing high-quality imaging data, which is vital for subsequent applications such as radiogenomics.

    Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Key Participants And Competitive Landscape

    Major companies operating in the artificial intelligence (ai)-powered diagnostic radiogenomics devices market are Thermo Fisher Scientific Inc., Siemens Healthineers AG, Philips Healthcare (Koninklijke Philips N. V. ), GE HealthCare Technologies Inc., Agilent Technologies Inc., Canon Medical Systems Corporation, Tempus AI Inc., Aidoc Medical Ltd., Owkin Inc., SOPHiA GENETICS SA, Lunit Inc., Synaptive Medical Inc., Median Technologies SA, Perspectum Ltd., Quibim S. L., Seno Medical Instruments Inc., Ultromics Limited, QMENTA Inc., Imbio LLC, Mirada Medical Limited, VUNO Inc., Radiomics. bio Inc., Qlucore AB, CureMetrix Inc.

    View The Full Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Report:

    https://thebusinessresearchcompany.com/report/artificial-intelligence-ai-powered-diagnostic-radiogenomics-devices-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

    Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Geographic Analysis: Where Is Demand Rising Fastest?

    North America was the largest region in the artificial intelligence (AI)-powered diagnostic radiogenomics devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-powered diagnostic radiogenomics devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Reach Out To Our Team:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Opportunities Are Emerging Beyond Traditional Growth Areas

    Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

    #Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Size And Revenue Forecast Through 2030

    The artificial intelligence (AI)-powered diagnostic radiogenomics devices market has demonstrated rapid expansion in recent years. This market is expected to grow from $0.62 billion in 2025 to $0.74 billion in 2026, achieving a compound annual growth rate (CAGR) of 19.2%. Historically, this expansion can be attributed to the rising prevalence of chronic and complex diseases, the increased adoption of advanced diagnostic imaging technologies, greater investment in precision medicine research initiatives, the broader application of genomic sequencing and molecular profiling, and the escalating demand for data-driven clinical decision-making solutions.

    The artificial intelligence (AI)-powered diagnostic radiogenomics devices market is projected for significant expansion in the coming years, with its size expected to reach $1.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 19.5%. This notable growth is largely attributable to several factors, including the increasing demand for AI-enabled personalized treatment planning solutions, the rising adoption of cloud-based radiogenomic data analytics platforms, the growing integration of genomics into diagnostic imaging workflows, a surge in investment towards oncology and neurology precision diagnostics, and a heightened focus on early disease detection and predictive healthcare technologies. Furthermore, major trends anticipated during this forecast period encompass the increasing adoption of multimodal imaging and genomics integration platforms, a growing demand for personalized and precision diagnostic solutions, the rising utilization of predictive analytics for disease prognosis and therapy response assessment, the increasing implementation of automated radiogenomic data interpretation tools, and an expanding emphasis on real-time clinical decision support within diagnostic workflows.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample_request?id=48488920&type=smp

    #Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Growth Factors: Which Forces Are Supporting Market Expansion?

    The increasing use of precision medicine approaches is projected to drive the expansion of the AI-powered diagnostic radiogenomics devices market in the coming years. Precision medicine refers to medical strategies that customize disease prevention, diagnosis, and treatment based on individual genetic, environmental, and lifestyle differences. The rise in precision medicine adoption is primarily fueled by the growing incorporation of genomic data into clinical decision-making within advanced healthcare systems. AI-powered diagnostic radiogenomics devices support this development by combining medical imaging with genomic data to facilitate accurate disease profiling, early diagnosis, and personalized treatment planning. For instance, in February 2024, a report from the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, highlighted that more than one-third of new drug approvals by the U. S. Food and Drug Administration were personalized therapies for four consecutive years through 2023. Therefore, the increasing embrace of precision medicine approaches is stimulating the growth of the AI-powered diagnostic radiogenomics devices market.

    Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Segmentation: How Is The Market Structured Across Key Categories?

    The artificial intelligence (ai)-powered diagnostic radiogenomics devices market covered in this report is segmented –

    1) By Component: Hardware, Software, Services

    2) By Imaging Modality: Magnetic Resonance Imaging, Computed Tomography, Positron Emission Tomography, Ultrasound, X-Ray Or Mammography, Multi-Modal Fusion

    3) By Application: Oncology, Neurology, Cardiology, Infectious Diseases

    4) By End User: Hospitals And Clinics, Diagnostic Imaging Centers, Academic And Research Institutes And Biobanks, Pharmaceutical And Biotechnology Companies And Contract Research Organizations, Government And Public Health Programs

    Subsegments:

    1) By Hardware: Imaging Sensors, Computational Processing Units, Data Storage Systems, Networking And Connectivity Modules, User Interface Devices

    2) By Software: Radiogenomic Analysis Software, Artificial Intelligence Diagnostic Algorithms, Image Processing And Enhancement Software, Data Visualization And Reporting Tools, Machine Learning Model Management Software

    3) By Services: Installation And Setup Services, Calibration And Maintenance Services, Training And Support Services, Data Management And Integration Services, Clinical Workflow Optimization Services

    Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Industry Trends: What Changes Are Reshaping Demand?

    Leading companies in the AI-powered diagnostic radiogenomics devices market are increasingly prioritizing technological innovations, particularly imaging quality assessment tools, to boost diagnostic precision and consistency. An imaging quality assessment tool operates as a software system, employing advanced algorithms to appraise, standardize, and ensure the dependability of medical imaging information. For instance, in June 2025, Quibim, a medical imaging technology company from Spain, introduced AI-QUAL. This solution uses artificial intelligence to automatically evaluate the quality of prostate magnetic resonance imaging, assign standardized scores, and identify artifacts that could affect diagnostic outcomes. The tool streamlines radiology workflows and aids in more reliable clinical decision-making by guaranteeing high-quality imaging data, which is crucial for subsequent applications such as radiogenomics.

    Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Competitive Landscape And Leading Companies

    Major companies operating in the artificial intelligence (ai)-powered diagnostic radiogenomics devices market are Thermo Fisher Scientific Inc., Siemens Healthineers AG, Philips Healthcare (Koninklijke Philips N. V. ), GE HealthCare Technologies Inc., Agilent Technologies Inc., Canon Medical Systems Corporation, Tempus AI Inc., Aidoc Medical Ltd., Owkin Inc., SOPHiA GENETICS SA, Lunit Inc., Synaptive Medical Inc., Median Technologies SA, Perspectum Ltd., Quibim S. L., Seno Medical Instruments Inc., Ultromics Limited, QMENTA Inc., Imbio LLC, Mirada Medical Limited, VUNO Inc., Radiomics. bio Inc., Qlucore AB, CureMetrix Inc.

    Access The Complete Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Report:

    https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-powered-diagnostic-radiogenomics-devices-market-report

    Artificial Intelligence (AI)-Powered Diagnostic Radiogenomics Devices Market Leading Geography: Which Region Generates The Most Revenue?

    North America was the largest region in the artificial intelligence (AI)-powered diagnostic radiogenomics devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-powered diagnostic radiogenomics devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model